SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb

Dysregulated activation of the complement system is implicated in the onset or progression of several diseases. Most clinical-stage complement inhibitors target the inactive complement proteins present at high concentrations in plasma, which increases target-mediated drug disposition and necessitate...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajagopal, Vaishnavi, Leksa, Nina, Gorham, Ronald, Jindal, Siddharth, Nair, Soumya, Knockenhauer, Kevin, Chan, Joanne, Byun, Tony, Mercadante, Courtney, Moore, Stephen, Panicker, Sandip, Parry, Graham, Storek, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424147/
https://www.ncbi.nlm.nih.gov/pubmed/36897252
http://dx.doi.org/10.1182/bloodadvances.2022009028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424147/
https://www.ncbi.nlm.nih.gov/pubmed/36897252
http://dx.doi.org/10.1182/bloodadvances.2022009028

Ejemplares similares